DDInter1382 DDInter1376
Palonosetron (INN, trade name Aloxi) is an antagonist of 5-HT3 receptors that is indicated for the prevention and treatment of chemotherapy-induced nausea and vomiting (CINV). It is the most effective of the 5-HT3 antagonists in controlling delayed CINV nausea and vomiting that appear more than 24 hours after the first dose of a course of chemotherapy and is the only drug of its class approved for this use by the U.S. Food and Drug Administration. As of 2008, it is the most recent 5-HT3 antagonist to enter clinical use.
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Palonosetron {u} (Compound) resembles {v} (Compound) Praziquantel
Palonosetron {u} (Compound) binds {v} (Gene) HTR3A
Palonosetron {u} (Compound) is included by {v} (Pharmacologic Class) Serotonin 3 Receptor Antagonists
Palonosetron {u} (Compound) causes {v} (Side Effect) Malnutrition
Palonosetron {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Palonosetron {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ezogabine
Palonosetron {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Fluconazole
Palonosetron {u} may lead to a major life threatening interaction when taken with {v} Lefamulin
Palonosetron {u} may lead to a major life threatening interaction when taken with {v} Mirtazapine
Palonosetron (Compound) resembles Praziquantel (Compound)
Palonosetron (Compound) binds HTR3A (Gene)
Palonosetron (Compound) is included by Serotonin 3 Receptor Antagonists (Pharmacologic Class)
Palonosetron (Compound) causes Malnutrition (Side Effect)
Palonosetron may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Palonosetron may cause a moderate interaction that could exacerbate diseases when taken with Ezogabine
Palonosetron may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole
Palonosetron may lead to a major life threatening interaction when taken with Lefamulin
Palonosetron may lead to a major life threatening interaction when taken with Mirtazapine